Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 in Subjects With Frequent Urticaria Flares

NCT05496465 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
21
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

ARS Pharmaceuticals, Inc.